Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 649 of 5804
-
One-Shot antibody shields kids from malaria in landmark trial
Disease control CompletedThe purpose of this study is to evaluate the safety and tolerability of one-time subcutaneous (SC) administration of monoclonal antibody (MAb) L9LS in healthy Kenyan children aged 5 months to 10 years, as well as the protective efficacy of one or two doses of L9LS against natural…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New shot could tame Flare-Ups in ulcerative colitis patients
Disease control OngoingThe purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Heavy weights vs. light weights: which builds better bones?
Disease control CompletedOsteoporosis is a bone disease that can result in fractures, disability and an increased risk of premature death. Exercise is recommended for fall and fracture prevention, but health care professionals often recommend walking or lower intensity community exercise classes, which m…
Phase: NA • Sponsor: University of Waterloo • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New vaccine aims to stop deadly salmonella strains
⭐️ VACCINE ⭐️ CompletedThe purpose of this study is to assess the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate (iNTS-TCV) candidate vaccine to be administere…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:00 UTC
-
Promising drug cocktail aims to stop breast cancer recurrence
Disease control Recruiting nowThis is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Phase: PHASE2 • Sponsor: Oana Danciu • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Eye implant could restore sight in advanced AMD
Disease control Recruiting nowThe objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision impairment associated with end-stage Age-related Macular Deg…
Phase: NA • Sponsor: VisionCare, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo therapy aims to wipe out CLL cells in untreated patients
Disease control Recruiting nowThis phase II trial tests whether acalabrutinib in combination with venetoclax or obinutuzumab works to shrink tumors in patients with treatment-naive chronic lymphocytic leukemia . Acalabrutinib is also an inhibitor that works in the body to block the activation of certain cells…
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Which comes first? new study aims to optimize AML treatment sequence
Disease control Recruiting nowThis phase II study compares the order of treatment with ivosidenib or enasidenib and azacitidine plus venetoclax in treating older patients with acute myeloid leukemia with genetic changes in the IDH1 or IDH2 genes (IDH mutated). Ivosidenib is in a class of medications called is…
Phase: PHASE2 • Sponsor: Alice Mims • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug duo aims to keep leukemia in check longer
Disease control OngoingA study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New pill shows promise against childhood brain tumor
Disease control Recruiting nowThe current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Phase: PHASE2 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope: pill may stop remaining lung spots from becoming cancer
Disease control Recruiting nowThis study designed to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage I lung adenocarcinoma.
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Can a daily pill keep leftover lung spots from turning into cancer?
Disease control Recruiting nowThis is an open label, phase II study to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage IB-IIIA lung adenocarcinoma.
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a common diabetes drug save heart failure patients?
Disease control Recruiting nowThe EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high r…
Phase: PHASE3 • Sponsor: Juntendo University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New cocktail of drugs and radiation takes on tough lung cancer
Disease control CompletedThis is a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC).
Phase: PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Crohn's patients may avoid unnecessary drugs after surgery, new study suggests
Prevention Recruiting nowWith this prospective, randomized, multicentre, parallel group pragmatic non-inferiority trial, the investigators will evaluate if endoscopy-driven introduction of biological therapy is not leading to more postoperative endoscopic recurrence at week 86 compared to systematic prop…
Phase: PHASE4 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Peanut allergy pill shows promise in early trial
Disease control CompletedThis clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.
Phase: PHASE1, PHASE2 • Sponsor: ALK-Abelló A/S • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail takes on seven tough cancers
Disease control Recruiting nowTROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Hope for Alzheimer's agitation: new drug shows promise in major trial
Symptom relief CompletedThis trial is a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
New drug aims to tame rare blood disorder flares
Disease control Recruiting nowThis is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Weight-Loss drug semaglutide tested as heart failure treatment
Symptom relief ENROLLING_BY_INVITATIONThe purpose of this research is to find out if an aggressive intervention to lose weight, will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as the obese phenotype of heart failure with preserved ejection fraction (HFpEF).
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC